BACE1 and Mental deterioration: An orally-available, brain-permeable small-molecule therapeutic that inhibits BACE1 cleavage of APP would overcome those limitations and, as a maintenance therapy, would not only decrease amyloid plaque formation, but also the upstream formation of the Aβ oligomers that are implicated in synaptic loss and cognitive decline [11,20].